This is an observational patient registry with no experimental treatment, following standard of care. We will use information derived from Connect Care regarding patients with IBD under the care of Gastroenterologists who are physicians at the respective University Hospitals. The primary objective is to develop and implement an Alberta registry to collect real-world data on biologics and advanced therapies in IBD patients to facilitate research and quality improvement projects. The registry will seek to enroll all persons who either have IBD or are being evaluated for a possible diagnosis of IBD at participating sites.

This project aims to understand the experiences and opinions of people on the autism spectrum, their families, and physicians who care for them regarding genetic testing in order to identify barriers and develop solutions. The study plans to enroll 300 families with at least one person on the autism spectrum and 50 physicians caring for people on the autism spectrum. It involves a consent procedure, an electronic survey, and an interview after one year. Genetic testing is important but not standardized in the clinical care of autism. The researchers aim to inform future interventions to increase rates of genetic counselling and testing to improve clinical care.

The purpose of this study is to evaluate and compare the effectiveness of percutaneous coronary intervention (PCI) against coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease (CAD) and ischemic left ventricular dysfunction (iLVSD). Both procedures are standard of care for patients with multivessel CAD and iLVSD. It is unclear whether PCI or CABG result in better, long-term health outcomes. The purpose of this study is to determine if one is better than the other.

REM sleep behavior disorder (RBD) is a disorder where a person "acts out their dreams" while sleeping. RBD is often associated with developing diseases like Parkinson’s disease and dementia with Lewy bodies. The purpose of this study is to carefully follow people with RBD over time in order to find new ways of predicting who is at risk of developing Parkinson's disease or dementia. This is vital in order to find a way to stop these diseases from occuring

This study is testing a drug called bitopertin to see if it can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without skin pain or burning. These rare conditions cause a substance called protoporphyrin IX to build up in the blood, which can lead to painful skin reactions to sunlight and whcih may affect the liver. Bitopertin may lower this substance in the body. Participants will receive either bitopertin or a placebo (a look-alike pill with no active medicine) to compare results. The study will also look at how participants feel on the treatment and how well they tolerate any side effects.

This study aims to assess the diet quality of people of South Asian descent living with Inflammatory Bowel disease (IBD) in Edmonton, Alberta. We are interested in understanding the diet quality of South Asians in Alberta and tailor the nutrition resources based on our findings. We aim to develop culturally adapted nutrition education materials. To do so, we are conducting interviews with South Asians living with IBD in Alberta to help us improve the existing nutrition handouts and make them more culturally oriented with information on traditional foods. This study invites South Asians in Alberta to contribute to the development of useful and relevant nutrition information resources.

The REVEAL study is a clinical trial evaluating an study drug, ION582, in individuals with Angelman syndrome. Currently, there are no approved therapies that address the underlying cause of Angelman syndrome. ION582 is being studied as a potential treatment for Angelman syndrome. This study is done to find out how safe and effective ION582 is in treating Angelman syndrome compared to placebo. Placebo looks the same as ION582 but does not have any medicine-related effects on the body. The REVEAL study will also evaluate ION582’s impact on communication, intellectual ability, motor skills, seizures, and sleep among other important factors.

About one third of patients with depression fail to respond to standard treatments and are considered treatment resistant (TRD). Ketamine has emerged as a potent therapy for TRD. Despite its benefits, there is limited data about the effectiveness and tolerability of sublingual ketamine treatment. Sublingual ketamine, unlike the more popular intravenous ketamine treatment, has several advantages including ease of use, cost-effectiveness, and the possibility of broader dissemination, including home-based administration. Therefore, this study aims to support the available evidence, by observing the effects of Sublingual ketamine in real world clinical practice.

Semaglutide is a medication widely prescribed to treat type 2 diabetes and obesity by lowering blood sugar and helping with weight loss. However, recent studies suggest that a significant portion of this weight loss may come from muscle mass, including heart muscle, which plays a crucial role in strength, movement, and overall health. This study aims to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

Brain derived neurotrophic factor (BDNF) is a protein known for protecting the brain by activating a specific receptor called tropomysin related kinase B (TrkB). Changes in BDNF/TrkB have been linked to certain brain diseases like amyotrophic lateral sclerosis (ALS). BDNF is known for its protective effects, but too much activation of BDNF/TrkB can actually harm motor neurons. In ALS, increased BDNF release causes excessive neuronal activity, leading to subsequent degeneration of motor neurons. To better understand how BDNF and its receptor TrkB affect the progression of ALS, we want to study their role, using a specialized brain scan, called “Quantitative [18F]TRACK-PET/MRI”.